Remodeling Tumor Immunogenicity with Dual-Activatable Binary CRISPR Nanomedicine for Cancer Immunotherapy

Yumeng Xing,Jianhui Yang,Yunlong Wang,Chun Wang,Zheng Pan,Fei-Long Liu,Yang Liu,Qi Liu

DOI: https://doi.org/10.1021/acsnano.2c12107

IF: 17.1

2023-03-11

ACS Nano

Abstract:The specific recognition of cancer cells by the body's immune system is an essential step in initiating antitumor immunity. However, the decreased expression of major histocompatibility complex class I (MHC-1) and overexpression of programmed death ligand 1 (PD-L1) causes insufficient tumor-associated antigens presentation and inactivation of T cells, which accounts for poor immunogenicity. To remodel tumor immunogenicity, herein, a dual-activatable binary CRISPR nanomedicine (DBCN) that can...

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology